MintNeuro, a semiconductor company building specialised chips for neural devices from implants to wearables, today announces a $5 million investment round to drive its commercial scale-up. MintNeuro’s chips give device developers better performance than generic components, with less risk, lower cost and a faster route to market than custom chip design. The funding will accelerate product launch, expand delivery of pre-release silicon to partners and grow the company’s international presence. The round was led by Odyssey Ventures, with participation from 33East, JSK Investments and Alumni Ventures, and returning investment from Empirical Ventures, Jumpspace Ventures and early investors. Bringing together deep tech, medtech and early-stage investors across Europe and the US, the round reflects global demand for the hardware needed to scale neurotechnology. MintNeuro has already delivered working silicon and reached key integration milestones with research and development partners, including Motif Neurotech and Amber Therapeutics. Earlier this year, MintNeuro announced a partnership and multi-year commercial chip supply agreement with Motif, supporting the development of Motif’s minimally invasive neurostimulator initially targeting treatment-resistant depression. A growing number of neural device companies are now evaluating or integrating MintNeuro’s technology, alongside research teams building implantable systems that connect directly to the brain and nervous system. MintNeuro will use the investment to grow its engineering and commercial teams, bring its products to market, support customers as they adopt its chips and strengthen its presence in the US alongside its UK and European base. Neural devices are opening new ways to understand and treat conditions across neurology, mental health and beyond, from Parkinson’s disease, epilepsy and depression to hearing loss and inflammatory disease. These technologies include brain-computer interfaces (BCIs), neuromodulation systems, sensory prostheses and bioelectronic medicines. Until now, progress across the industry has been held back by the lack of standard chips designed specifically for the extreme power, size, safety and signal-quality demands of these devices. MintNeuro is closing that gap with a modular semiconductor platform purpose-built for core functions like neural sensing, signal processing and stimulation: listening to the body’s nerve signals, interpreting them, and delivering precise electrical pulses to treat disease or restore function. Instead of adapting generic components or funding years of custom chip design, developers can build on MintNeuro’s chips to create smaller, lower-power neural devices and move from research to clinical use sooner. MintNeuro’s modular architecture provides the building blocks to combine sensing, processing and stimulation efficiently at the system level, supporting more integrated closed-loop interfaces with the nervous system. Commenting on the investment, Dorian Haci, Co-Founder and CEO of MintNeuro, said: “Every neural device depends on the chips inside it. Today, most device and therapy developers still have to choose between generic components that were never designed for the body and years of custom chip development. We are building the chips that end that trade-off. This funding moves us from technology validation to commercial scale-up, with more customer programmes, faster product launches and our chips in the hands of many more developers. Our ambition is clear: to make MintNeuro the semiconductor platform the global neurotechnology industry builds on.” Michelle Robson, Founding Partner at Odyssey Ventures, said: “Neural devices such as BCIs represent one of the most exciting frontier technology opportunities today, and significant value will accrue to those solving the foundational infrastructure challenges that stand between innovation and widespread adoption. MintNeuro has the technology, market pull and ambition to be